Evidence map›Paper›PMID 41461629›Full record

ReviewZeitschrift fur Rheumatologie2026

[Change of perspectives-goals in pediatric rheumatology].

Johannes-Peter Haas, Phil Oliver Ladehof

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Rheumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Johannes-Peter HaasDeutsches Zentrum für Kinder- und Jugendrheumatologie, Kinderklinik Garmisch-Partenkirchen, Gehfeldstr. 24, 82467, Garmisch-Partenkirchen, Deutschland. haas.johannes-peter@rheuma-kinderklinik.de.
Phil Oliver Ladehof, Flensburg, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past 25 years, the results of treatment in pediatric rheumatology have greatly improved due to enormous developments in medical therapies. Today, reaching inactive disease or remission has become a realistic aim. Controlling inflammation and avoiding damage still remain the most important issues. Scores and tools for the measurement of disease activity have mostly been designed to be applicable in studies. Priorities may be different in a patient's perspective. This paper illustrates the different perspectives from a patient's and physician's view, thus, trying to describe the requirement, potentials, and limitations of shared decision-making in children, adolescents and young adults suffering from rheumatic diseases.

Indexed as

Antirheumatic AgentsArthritis, JuvenilePatient ParticipationPediatricsRheumatic DiseasesRheumatologyAdolescentChildFemaleGermanyHumansMaleYoung AdultAntirheumatic AgentsPatients’ perspectivePediatric rheumatologyRemissionShared decision makingTreat-to-target

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.